Patient description: The patient is a 63-year-old man presenting to the Emergency Department with a history of acute urinary retention in the past 2 days. Abdominopelvic CT scan revealed a large prostate and a bladder filled with urine. He is a candidate for urethral catheterization and TURP. Further evaluation revealed: Post-void residual: 71 mL Prostate volume (TRUS): 63 mL Prostate-specific antigen (PSA) level: 3.5 ng/mL His recent blood chemistry (3 days ago) was normal: Hgb: 13.6 g/dl WBC: 133000 /mm3 Plt: 370000 /ml PT: 12 second PTT: 34 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Carcinoma, Squamous Cell of Head and Neck Each patient must meet all of the following to be enrolled in the study Patients must have histologically confirmed squamous cell carcinoma, undifferentiated carcinoma, or poorly differentiated carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx with no evidence of distant metastasis. Biopsy sampling of primary tumor with pathology report documentation of confirmed diagnostic tissue type is required. Patients should be evaluated by a Radiation Oncologist, Medical Oncologist and Otolaryngologist prior to enrolling on study Patients must have high risk or intermediate risk disease, defined below. Staging evaluation should be determined by imaging studies and complete head and neck exam in accordance with the American Joint committee on Cancer Staging Manual, 7th edition o High risk patients must meet one of the following Unresectable oral cavity Larynx: T4 any N; T2-3 and ≥N2a Hypopharynx and p16(-) oropharynx: Stage III-IVb except T1N1 p16(-) Oropharnyx: Stage III-IVb except T1N1 o Intermediate risk, p16(+) oropharynx patients must meet one of the following T3 or ≥ N2a AND ≥10 pack-years tobacco exposure (See Tobacco Assessment Form, Appendix A) T4 disease, irrespective of smoking status N3 disease, irrespective of smoking status Note: for oropharyngeal patients, p16 status must be known, and can be performed at the local site. p16-positive disease is defined as ≥70% of tumor cells demonstrating diffuse nuclear and cytoplasmic staining by p16 immunohistochemistry (IHC). A positive test for HPV-16 by in-situ hybridization (ISH), if this is the local site preference for assessing HPV status, may substitute for p16 IHC testing. p16 staining is not required for non-oropharyngeal sites  Patients meeting any of the following are not to be enrolled in the study History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent Distant metastatic disease including CNS or leptomeningeal metastases is not allowed Left ventricular ejection fraction (LVEF) ≤ 50% Significant pulmonary disease, including pulmonary hypertension or interstitial pneumonitis Decreased serum albumin < 30 g/L (< 3 g/dL) Peripheral edema ≥ Grade 2 per NCI-CTCAE version 4.0 Significant electrolyte imbalance prior to enrollment Hypomagnesemia < 1.2 mg/dL or 0.5 mmol/L